Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Quick Facts
What This Study Found
Tirzepatide reduced HbA1c by 1.24 to 2.58% and body weight by 5.4-11.7 kg.
Key Numbers
How They Did This
Five clinical trials (SURPASS 1-5) were conducted with type 2 diabetes patients, comparing tirzepatide to other treatments.
Why This Research Matters
This medication represents a significant advancement in diabetes treatment, potentially offering better management of blood sugar and weight. Understanding its mechanisms could lead to new therapies for diabetes and obesity.
What This Study Doesn't Tell Us
Further research is needed to fully understand tirzepatide's mechanisms and its long-term effects in humans.
Trust & Context
- Original Title:
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
- Published In:
- Cardiovascular diabetology, 21(1), 169 (2022)
- Authors:
- Nauck, Michael A(8), D'Alessio, David A(4)
- Database ID:
- RPEP-06392
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06392APA
Nauck, Michael A; D'Alessio, David A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.. Cardiovascular diabetology, 21(1), 169. https://doi.org/10.1186/s12933-022-01604-7
MLA
Nauck, Michael A, et al. "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.." Cardiovascular diabetology, 2022. https://doi.org/10.1186/s12933-022-01604-7
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the tr..." RPEP-06392. Retrieved from https://rethinkpeptides.com/research/nauck-2022-tirzepatide-a-dual-gipglp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.